Neurologic Disorders

Evidence for Clobazam Monotherapy Use in Focal, Generalized Seizures Reviewed

By July 17, 2018

Researchers searched various databases to identify trials that compared clobazam monotherapy to placebo or another antiepileptic drug in patients with ≥2 unprovoked seizures or a single acute symptomatic seizure requiring short-term continuous treatment.

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

By July 16, 2018

Currently, there are no approved treatments for behavioral symptoms (eg, aggression, agitation) in Alzheimer's disease.

Vigadrone Available for Refractory Complex Partial Seizures, Infantile Spasms

By July 16, 2018

Like Sabril, Vigadrone carries a Boxed Warning regarding the risk of permanent vision loss and is only available to healthcare professionals and patients under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program

Blister Packs for Several Meds Recalled Due to Risk of Harm to Children

By July 09, 2018

The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.

Xeomin Approved to Treat Chronic Sialorrhea in Adults

By July 05, 2018

The approval was supported by data from a Phase 3, randomized, double-blind, placebo-controlled, multicenter (N=184) trial.

FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Next-Generation Sequencing May Improve Pediatric Epilepsy Tx

June 29, 2018

By testing type, detection rates were 32.6% for the epilepsy-related gene panel, 44.8% for the clinical WES gene panel, and 17.3% for WES.

First Marijuana-Based Drug Approved to Treat LGS, Dravet Syndrome

By June 25, 2018

This marks the first approved drug that contains an active ingredient derived from marijuana as well as the first treatment approved for patients with Dravet syndrome.

Parkinson's Medications Tied to Impulse Control Disorders

June 21, 2018

The 5-year cumulative incidence of ICDs was 46.1% in 306 patients without ICDs at baseline (DA ever-users, 51.5%; DA never users, 12.4%).

Florida Teen First Human Case of Another Mosquito-Borne Virus

June 21, 2018

"This virus is part of a group commonly known as the California serogroup of viruses," first author, John Lednicky, PhD. "These viruses are known to cause encephalitis in several species, including humans."

Incidence of Extrapyramidal Symptoms Higher With Certain Antidepressants

By June 18, 2018

Within the cohort, 3838 cases were identified and compared with 38,380 age-matched controls.

Walk Test IDs Risk of Cognitive Dysfunction Post Cardiac Surgery

June 15, 2018

"If we are able to identify patients who are at risk for POCD, we can provide early treatment and encourage them to better understand the dysfunction," Hayashi said in a statement.

Foods With Fat and Carbohydrate Are More Highly Valued

June 15, 2018

Individuals were better able to estimate the energy density of fat vs carbohydrate and fat + carbohydrate foods. This effect correlated with functional connectivity between the fusiform gyrus and ventromedial prefrontal cortex (visual and valuation areas).

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson's Disease

By June 13, 2018

The film is a new formulation of the dopamine agonist apomorphine, intended for rapid conversion from the OFF to the ON state; it has been studied to treat motor OFF episodes up to 5 times a day.

Dexmedetomidine Cuts γ-Aminobutyric Acid Receptor Function

June 13, 2018

The researchers found that dexmedetomidine reduced the etomidate-induced sustained increase in α5 γ-aminobutyric acid type A receptor cell-surface expression (etomidate: 146.4 ± 51.6%; etomidate + dexmedetomidine: 118.4 ± 39.1% of control).

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

By June 12, 2018

The independent data monitoring committee (IDMC) concluded that the 2 trials (AMARANTH and DAYBREAK-ALZ) investigating the treatment in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints of change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale.

Long-Term Type 1 Diabetes Associated With Cognitive Decline

June 12, 2018

Researchers compared cognition in 82 individuals with 50 or more years of type 1 diabetes (Medalists), 31 age-matched individuals with type 2 diabetes, and 30 age-matched control subjects without diabetes.

Intellectual Activities in Later Life May Cut Dementia Risk

June 07, 2018

After those who developed dementia within 3 years after baseline were excluded and after adjustment for health behaviors, physical and psychiatric comorbidities, and sociodemographic factors, the estimated odds ratio for incident dementia was 0.71 for those with intellectual activities at baseline.

Fycompa Granted Priority Review for Pediatric Indications

By May 30, 2018

The sNDA included data from Study 311 (N=180), an ongoing, open-label, multicenter trial with an extension phase that evaluated the safety, tolerability, and exposure-efficacy relationship of Fycompa oral suspension as adjunctive therapy in children (4 to 11 years) with inadequately controlled POS or PGTC seizures.

Neurologists Identify New Type of Vertigo

May 25, 2018

Over a median follow-up of 12 years from symptom onset, long-term prognosis was favorable, with a resolution or improvement of the symptoms in more than half of the patients, with none developing VM, MD, or cerebellar dysfunction.

Lenti-D Gets Breakthrough Tx Designation for Cerebral Adrenoleukodystrophy

By May 24, 2018

This investigational lentiviral-based gene therapy is currently being studied in the Phase 2/3 Starbeam Study, a 2-year study assessing the safety and efficacy of Lenti-D in boys ≤17 years old with CALD.

Studies Halted for Alzheimer's Candidate Atabecestat Due to Safety Concerns

By May 23, 2018

Janssen said in a statement that they are informing study participants (N>600), trial investigators, health authorities, ethics committees and institutional review boards about the situation.

FDA: Possible Risk of Neural Tube Birth Defects With Certain HIV Meds

By May 18, 2018

The Agency has received reports of serious neural tube birth defects involving the brain, spine, and spinal cord in babies born to women who received dolutegravir for HIV treatment.

Aerobic + Strength Exercise Doesn't Slow Cognitive Decline

May 17, 2018

The researchers found that the mean Alzheimer's disease assessment scale-cognitive subscale score had increased to 25.2 and 23.8 in the exercise arm and usual care group, respectively, by 12 months (adjusted between-group difference, −1.4), indicating greater cognitive impairment in the exercise group

Addition of Cannabidiol May Cut Drop Seizures in Lennox-Gastaut

May 17, 2018

"The addition of cannabidiol at a dose of 10mg or 20mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo," the authors write.

Better Diet Quality Associated With Larger Brain Volume

May 17, 2018

Specifically, larger brain volume was associated with high intake of vegetables, fruit, whole grains, nuts, dairy, and fish, and low intake of sugar-containing beverages.

Surgical repair improves survival, pain control in patients with dementia who suffer hip fracture

May 15, 2018

In this retrospective study, nursing home patients with dementia who had a hip fracture had improved survival if they underwent surgical repair compared to non-surgical management.

FDA Approves First MS Treatment for Pediatric Patients

By May 14, 2018

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Briviact Approved for Pediatric Patients With Partial-Onset Seizures

By May 14, 2018

The expanded approval was supported by extrapolated efficacy data from placebo-controlled studies in adults with partial-onset seizures.

Primary Care Providers Have Mixed Views on Genetic Tests

May 14, 2018

They find tests for genetic risk potentially useful, but lack confidence in interpreting results